{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T14:03:44Z","timestamp":1784988224956,"version":"3.55.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["L248022"],"award-info":[{"award-number":["L248022"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005150","name":"Chinese Academy of Medical Sciences","doi-asserted-by":"publisher","award":["2021-I2M-1-003"],"award-info":[{"award-number":["2021-I2M-1-003"]}],"id":[{"id":"10.13039\/501100005150","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"DOI":"10.1038\/s41392-026-02775-5","type":"journal-article","created":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T13:37:12Z","timestamp":1784986632000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Lenvatinib enhances the response of biliary tract cancer to anti-HER2 therapy"],"prefix":"10.1038","volume":"11","author":[{"given":"Huishan","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuofeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanhua","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyue","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7667-0615","authenticated-orcid":false,"given":"Nan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiran","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyu","family":"Xun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingnan","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dandan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longhao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingjian","family":"Piao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengjie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiongyuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boyu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3444-8044","authenticated-orcid":false,"given":"Haitao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"key":"2775_CR1","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","volume":"397","author":"JW Valle","year":"2021","unstructured":"Valle, J. W., Kelley, R. K., Nervi, B., Oh, D. Y. & Zhu, A. X. Biliary tract cancer. Lancet 397, 428\u2013444 (2021).","journal-title":"Lancet"},{"key":"2775_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-10286-z","volume":"22","author":"J Koshiol","year":"2022","unstructured":"Koshiol, J., Yu, B., Kabadi, S. M., Baria, K. & Shroff, R. T. Epidemiologic patterns of biliary tract cancer in the United States: 2001-2015. BMC Cancer 22, 1178 (2022).","journal-title":"BMC Cancer"},{"key":"2775_CR3","doi-asserted-by":"publisher","first-page":"403","DOI":"10.6004\/jnccn.2025.0042","volume":"23","author":"AB Benson 3rd","year":"2025","unstructured":"Benson, A. B. 3rd et al. Biliary tract cancers, Version 2.2025, NCCN clinical practice guidelines in oncology. J. Natl. Compr. Cancer Netw. 23, 403\u2013418 (2025).","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"2775_CR4","doi-asserted-by":"publisher","first-page":"EVIDoa2200015","DOI":"10.1056\/EVIDoa2200015","volume":"1","author":"DY Oh","year":"2022","unstructured":"Oh, D. Y. et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid. 1, EVIDoa2200015 (2022).","journal-title":"NEJM Evid."},{"key":"2775_CR5","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","volume":"401","author":"RK Kelley","year":"2023","unstructured":"Kelley, R. K. et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 401, 1853\u20131865 (2023).","journal-title":"Lancet"},{"key":"2775_CR6","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/j.jhep.2025.05.003","volume":"83","author":"DY Oh","year":"2025","unstructured":"Oh, D. Y. et al. Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study. J. Hepatol. 83, 1092\u20131101 (2025).","journal-title":"J. Hepatol."},{"key":"2775_CR7","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/S1470-2045(21)00027-9","volume":"22","author":"A Lamarca","year":"2021","unstructured":"Lamarca, A. et al. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. Lancet Oncol. 22, 690\u2013701 (2021).","journal-title":"Lancet Oncol."},{"key":"2775_CR8","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","volume":"21","author":"GK Abou-Alfa","year":"2020","unstructured":"Abou-Alfa, G. K. et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 21, 671\u2013684 (2020).","journal-title":"Lancet Oncol."},{"key":"2775_CR9","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/S2468-1253(21)00171-0","volume":"6","author":"AE Kam","year":"2021","unstructured":"Kam, A. E., Masood, A. & Shroff, R. T. Current and emerging therapies for advanced biliary tract cancers. Lancet Gastroenterol. Hepatol. 6, 956\u2013969 (2021).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"2775_CR10","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1056\/NEJMoa2206834","volume":"388","author":"L Goyal","year":"2023","unstructured":"Goyal, L. et al. Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma. N. Engl. J. Med 388, 228\u2013239 (2023).","journal-title":"N. Engl. J. Med"},{"key":"2775_CR11","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.jhep.2022.09.004","volume":"78","author":"JJ Harding","year":"2023","unstructured":"Harding, J. J., Khalil, D. N., Fabris, L. & Abou-Alfa, G. K. Rational development of combination therapies for biliary tract cancers. J. Hepatol. 78, 217\u2013228 (2023).","journal-title":"J. Hepatol."},{"key":"2775_CR12","doi-asserted-by":"crossref","unstructured":"Lee S. S. et al. HER2-positivity as a prognostic biomarker and therapeutic target in advanced biliary tract cancer: a multi-institutional analysis. Clin. Cancer Res. 32, 1745\u20131754 (2026).","DOI":"10.1158\/1078-0432.CCR-25-2153"},{"key":"2775_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70560","volume":"7","author":"H Lei","year":"2026","unstructured":"Lei, H. et al. Breast cancer: molecular pathogenesis, targeted therapy, screening, and prevention. MedComm 7, e70560 (2026).","journal-title":"MedComm"},{"key":"2775_CR14","doi-asserted-by":"publisher","unstructured":"Choo J. et al. Advances in the management of metastatic gastric cancer: current strategies and emerging therapeutics. Nat. Rev. Clin. Oncol. https:\/\/doi.org\/10.1038\/s41571-026-01134-1 (2026).","DOI":"10.1038\/s41571-026-01134-1"},{"key":"2775_CR15","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s10555-016-9645-x","volume":"36","author":"S Galdy","year":"2017","unstructured":"Galdy, S. et al. HER2\/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target? Cancer Metastasis Rev. 36, 141\u2013157 (2017).","journal-title":"Cancer Metastasis Rev."},{"key":"2775_CR16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.humpath.2020.08.006","volume":"105","author":"N Hiraoka","year":"2020","unstructured":"Hiraoka, N. et al. Details of human epidermal growth factor receptor 2 status in 454 cases of biliary tract cancer. Hum. Pathol. 105, 9\u201319 (2020).","journal-title":"Hum. Pathol."},{"key":"2775_CR17","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1200\/JCO.23.02005","volume":"42","author":"F Meric-Bernstam","year":"2024","unstructured":"Meric-Bernstam, F. et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial. J. Clin. Oncol. 42, 47\u201358 (2024).","journal-title":"J. Clin. Oncol."},{"key":"2775_CR18","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1016\/S1470-2045(21)00336-3","volume":"22","author":"M Javle","year":"2021","unstructured":"Javle, M. et al. Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol. 22, 1290\u20131300 (2021).","journal-title":"Lancet Oncol."},{"key":"2775_CR19","doi-asserted-by":"publisher","first-page":"5569","DOI":"10.1200\/JCO.23.00606","volume":"41","author":"Y Nakamura","year":"2023","unstructured":"Nakamura, Y. et al. Tucatinib and trastuzumab for previously treated human epidermal growth factor receptor 2-positive metastatic biliary tract cancer (SGNTUC-019): a phase II basket study. J. Clin. Oncol. 41, 5569\u20135578 (2023).","journal-title":"J. Clin. Oncol."},{"key":"2775_CR20","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/S1470-2045(23)00242-5","volume":"24","author":"JJ Harding","year":"2023","unstructured":"Harding, J. J. et al. Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study. Lancet Oncol. 24, 772\u2013782 (2023).","journal-title":"Lancet Oncol."},{"key":"2775_CR21","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S2468-1253(22)00335-1","volume":"8","author":"CK Lee","year":"2023","unstructured":"Lee, C. K. et al. Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19-14). Lancet Gastroenterol. Hepatol. 8, 56\u201365 (2023).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"2775_CR22","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1200\/JCO.23.01193","volume":"42","author":"V Ostwal","year":"2024","unstructured":"Ostwal, V. et al. Trastuzumab plus gemcitabine-cisplatin for treatment-na\u00efve human epidermal growth factor receptor 2-positive biliary tract adenocarcinoma: a multicenter, open-label, phase II study (TAB). J. Clin. Oncol. 42, 800\u2013807 (2024).","journal-title":"J. Clin. Oncol."},{"key":"2775_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100314","volume":"7","author":"MM Javle","year":"2022","unstructured":"Javle, M. M. et al. Varlitinib plus capecitabine in second-line advanced biliary tract cancer: a randomized, phase II study (TreeTopp). ESMO open 7, 100314 (2022).","journal-title":"ESMO open"},{"key":"2775_CR24","doi-asserted-by":"publisher","first-page":"3847","DOI":"10.2147\/CMAR.S188316","volume":"11","author":"M Capozzi","year":"2019","unstructured":"Capozzi, M. et al. Lenvatinib, a molecule with versatile application: from preclinical evidence to future development in anti-cancer treatment. Cancer Manag. Res. 11, 3847\u20133860 (2019).","journal-title":"Cancer Manag. Res."},{"key":"2775_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.785535","volume":"12","author":"Y Wang","year":"2022","unstructured":"Wang, Y. et al. Lenvatinib beyond first-line therapy in patients with advanced biliary tract carcinoma. Front. Oncol. 12, 785535 (2022).","journal-title":"Front. Oncol."},{"key":"2775_CR26","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/s41586-021-03741-7","volume":"595","author":"H Jin","year":"2021","unstructured":"Jin, H. et al. EGFR activation limits the response of liver cancer to lenvatinib. Nature 595, 730\u2013734 (2021).","journal-title":"Nature"},{"key":"2775_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2019.114428","volume":"460","author":"S Chen","year":"2019","unstructured":"Chen, S., Cao, Q., Wen, W. & Wang, H. Targeted therapy for hepatocellular carcinoma: Challenges and opportunities. Cancer Lett. 460, 1\u20139 (2019).","journal-title":"Cancer Lett."},{"key":"2775_CR28","first-page":"179","volume":"3","author":"R Wahdan-Alaswad","year":"2020","unstructured":"Wahdan-Alaswad, R., Liu, B. & AD, T. hor Targeted lapatinib anti-HER2\/ErbB2 therapy resistance in breast cancer: opportunities to overcome a difficult problem. Cancer Drug Resist. 3, 179\u2013198 (2020).","journal-title":"Cancer Drug Resist."},{"key":"2775_CR29","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jhep.2022.02.019","volume":"77","author":"CY Wei","year":"2022","unstructured":"Wei, C. Y. et al. PKC\u03b1\/ZFP64\/CSF1 axis resets the tumor microenvironment and fuels anti-PD1 resistance in hepatocellular carcinoma. J. Hepatol. 77, 163\u2013176 (2022).","journal-title":"J. Hepatol."},{"key":"2775_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s12957-023-02983-1","volume":"21","author":"JW Zhang","year":"2023","unstructured":"Zhang, J. W. et al. Clinical response to adding pyrotinib to pembrolizumab and lenvatinib for HER2-positive advanced intrahepatic cholangiocarcinoma: a case report. World J. Surg. Oncol. 21, 108 (2023).","journal-title":"World J. Surg. Oncol."},{"key":"2775_CR31","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/s41392-025-02409-2","volume":"10","author":"H Pan","year":"2025","unstructured":"Pan, H. et al. Tumor microenvironment delineates differential responders to trastuzumab emtansine in HER2-positive metastatic breast cancer patients previously treated with pyrotinib: an exploratory biomarker analysis of a phase II study (NJMU-BC02). Signal Transduct. Target. Ther. 10, 318 (2025).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2775_CR32","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1200\/JCO.22.02912","volume":"42","author":"X Sheng","year":"2024","unstructured":"Sheng, X. et al. Efficacy and safety of disitamab vedotin in patients with human epidermal growth factor receptor 2-positive locally advanced or metastatic urothelial carcinoma: a combined analysis of two phase II clinical trials. J. Clin. Oncol. 42, 1391\u20131402 (2024).","journal-title":"J. Clin. Oncol."},{"key":"2775_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-5223-7","volume":"19","author":"M Moehler","year":"2019","unstructured":"Moehler, M. et al. Safety and efficacy of afatinib as add-on to standard therapy of gemcitabine\/cisplatin in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, phase I trial with an extensive biomarker program. BMC Cancer 19, 55 (2019).","journal-title":"BMC Cancer"},{"key":"2775_CR34","doi-asserted-by":"crossref","unstructured":"Rahman A. et al. Inhibition of ErbB kinase signalling promotes resolution of neutrophilic inflammation. eLife. 8, e50990 (2019).","DOI":"10.7554\/eLife.50990"},{"key":"2775_CR35","doi-asserted-by":"publisher","first-page":"4564","DOI":"10.7150\/thno.68972","volume":"12","author":"Y Wu","year":"2022","unstructured":"Wu, Y. et al. FGFR blockade boosts T cell infiltration into triple-negative breast cancer by regulating cancer-associated fibroblasts. Theranostics 12, 4564\u20134580 (2022).","journal-title":"Theranostics"},{"key":"2775_CR36","doi-asserted-by":"publisher","first-page":"108844","DOI":"10.1016\/j.pharmthera.2025.108844","volume":"269","author":"Y Chu","year":"2025","unstructured":"Chu, Y., Yang, S. & Chen, X. Fibroblast growth factor receptor signaling in metabolic dysfunction-associated fatty liver disease: Pathogenesis and therapeutic targets. Pharmacol. Ther. 269, 108844 (2025).","journal-title":"Pharmacol. Ther."},{"key":"2775_CR37","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/s41571-024-00869-z","volume":"21","author":"M Katoh","year":"2024","unstructured":"Katoh, M. et al. FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions. Nat. Rev. Clin. Oncol. 21, 312\u2013329 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2775_CR38","doi-asserted-by":"publisher","first-page":"4154","DOI":"10.1158\/1078-0432.CCR-18-0078","volume":"24","author":"MA Lowery","year":"2018","unstructured":"Lowery, M. A. et al. Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: potential targets for intervention. Clin. Cancer Res. 24, 4154\u20134161 (2018).","journal-title":"Clin. Cancer Res."},{"key":"2775_CR39","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1158\/1078-0432.CCR-19-0353","volume":"26","author":"P Fern\u00e1ndez-Nogueira","year":"2020","unstructured":"Fern\u00e1ndez-Nogueira, P. et al. Tumor-associated fibroblasts promote HER2-targeted therapy resistance through FGFR2 activation. Clin. Cancer Res. 26, 1432\u20131448 (2020).","journal-title":"Clin. Cancer Res."},{"key":"2775_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30217-7","volume":"13","author":"Y Zou","year":"2022","unstructured":"Zou, Y. et al. N6-methyladenosine regulated FGFR4 attenuates ferroptotic cell death in recalcitrant HER2-positive breast cancer. Nat. Commun. 13, 2672 (2022).","journal-title":"Nat. Commun."},{"key":"2775_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-023-00462-0","volume":"7","author":"K Furugaki","year":"2023","unstructured":"Furugaki, K. et al. FGFR blockade inhibits targeted therapy-tolerant persister in basal FGFR1- and FGF2-high cancers with driver oncogenes. NPJ Precis. Oncol. 7, 107 (2023).","journal-title":"NPJ Precis. Oncol."},{"key":"2775_CR42","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/j.annonc.2022.08.001","volume":"33","author":"JE Augustin","year":"2022","unstructured":"Augustin, J. E., Soussan, P. & Bass, A. J. Targeting the complexity of ERBB2 biology in gastroesophageal carcinoma. Ann. Oncol. 33, 1134\u20131148 (2022).","journal-title":"Ann. Oncol."},{"key":"2775_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-021-02842-1","volume":"19","author":"MJ Mezynski","year":"2021","unstructured":"Mezynski, M. J. et al. Targeting the PI3K and MAPK pathways to improve response to HER2-targeted therapies in HER2-positive gastric cancer. J. Transl. Med. 19, 184 (2021).","journal-title":"J. Transl. Med."},{"key":"2775_CR44","doi-asserted-by":"crossref","unstructured":"Gu S. et al. Cryoablation plus sintilimab and lenvatinib in advanced or metastatic intrahepatic cholangiocarcinoma: a phase 2 trial. Nat. Cancer 7, 60\u201379 (2026).","DOI":"10.1038\/s43018-025-01058-2"},{"key":"2775_CR45","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.ejca.2016.03.082","volume":"62","author":"LH Schwartz","year":"2016","unstructured":"Schwartz, L. H. et al. RECIST 1.1\u2014Standardisation and disease-specific adaptations: perspectives from the RECIST Working Group. Eur. J. Cancer 62, 138\u2013145 (2016).","journal-title":"Eur. J. Cancer"},{"key":"2775_CR46","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","volume":"112","author":"A Freites-Martinez","year":"2021","unstructured":"Freites-Martinez, A., Santana, N., Arias-Santiago, S. & Viera, A. Using the common terminology criteria for adverse events (CTCAE\u2014Version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas Dermosifiliogr. 112, 90\u201392 (2021).","journal-title":"Actas Dermosifiliogr."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02775-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02775-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02775-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T13:37:14Z","timestamp":1784986634000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02775-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2775"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02775-5","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,8]]},"assertion":[{"value":"31 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"303"}}